Dow Dull Except for...
Health Care: Drugs
Bio-Path Holdings Inc. (BPTH: OTC)
$0.49 -0.05 | -9.26%
05/17/13 - 11:59 AM ET
2.80K / 13.10K
Vol / Avg. Vol:0.55 / 0.54
Open / Prev. Close:0.49 - 0.55
Today's Range:0.26 - 0.60
52 Wk Range:0.00%
Performance YTD:TheStreet Rating:
Portfolios with BPTH
- Portfolio NameUser Type
- UserJIM BOHEN Portfolio 1
Latest BPTH Headlines from TheStreet
Press Releases for BPTH
- Bio-Path Holdings Begins Enrollment In Fifth Cohort Of Phase I Clinical Trial Of Lead Product Candidate Liposomal Grb-2 In Leukemias - Business Wire 03.07.13 | 04:03 pm
- Bio-Path Holdings To Present At The Biotech Showcase™ 2013 Conference - Business Wire 01.03.13 | 09:01 am
- Bio-Path Holdings To Expand Development Of Liposomal Grb-2 Into Two Additional Indications: Triple Negative And Inflammatory Breast Cancers - Business Wire 12.06.12 | 09:12 am
- Bio-Path Holdings Reports Third Quarter 2012 Operational And Financial Results - Business Wire 11.16.12 | 09:11 am
- Bio-Path Holdings Successfully Completes Fourth Cohort In Phase I Clinical Trial Of Lead Product Candidate Liposomal Grb-2 In Leukemia - Business Wire 11.14.12 | 12:11 pm
- Bio-Path Holdings Adds New Board Member - Business Wire 10.04.12 | 11:10 am
- Bio-Path Holdings To Present At The 11th Annual BIO Investor Forum - Business Wire 10.03.12 | 09:10 am
- Bio-Path Holdings To Present At The Rodman & Renshaw Annual Global Investment Conference - Business Wire 09.04.12 | 12:09 pm
- Bio-Path Holdings To Present At The 2012 Southern California Investor Conference - Business Wire 08.23.12 | 12:08 pm
- Bio-Path Holdings Reports Second Quarter 2012 Operational And Financial Results - Business Wire 08.16.12 | 10:08 am
Partner Headlines for BPTH
- Biotechs to Watch at the 2012 San Francisco Healthcare Confrences - Analyst Blog - Zacks 01.09.12 | 07:01 am
